Profile of IL-1 beta, INF-gamma, IL-4 and IL-17 in patients with COVID-19

Resumen

The immune response to SARS-CoV-2 is mediated by several soluble chemotactic factors, including cytokines whose levels vary at different stages and types of infections. Clinical evidence shows that "cytokine storm," in which the body has high levels of several pro-inflammatory cytokines, is common in several patients with severe COVID-19. Thus, the aim of this study was to evaluate the inflammatory response mediated by the cytokines IL-1 Beta, INF-Gama, IL-4 and IL-17 in patients with COVID. Sandwich-type immunoenzymatic assays (ELISA sandwich) were performed to determine the serum cytokine concentration of a group of 11 patients with RT-PCR confirmed diagnoses compared to a control group (n=11). The samples were evaluated in duplicate and the statistical analyses of the results considered the measures of central tendency with the mean (Md). Thus, we found the results related to the different cytokines: IL-beta (patient = 138 pg/mL; control = 50 pg/mL); Interferon-gamma (patient= 104.25 pg/mL; control= 55 pg/mL); IL-4 (patient= 92.25 pg/mL; control 44 pg/mL); IL-17 (patient= 94.5 pg/mL; control 57 pg/mL). Understanding the variation in the levels of these mediators during pathology, through the analysis of the partial results of the project, is essential to elucidate the profile of the inflammatory response of patients with COVID-19.

DOI:https://doi.org/10.56238/sevenIIImulti2023-175